Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients with Moderate to High-Risk CMV Serostatus.

    Jun 23, 2025DOI: 10.1016/j.cardfail.2025.05.017Journal ArticleJCF

    Written by: Afsana RahmanChanghee LeeSalwa RahmanJulia BaranowskaCathrine M MoellerAndrea Fernandez ValledorGal RubensteinDaniel OrenAdel T AlnatourBrian LabarreKyung TaekDavid BaeJayant RaikhelkarDor LotanErsilia M DefilippisAdil A YunisJustin FriedFarhana LatifMelana YuzefpolskayaPaolo C ColomboEdward LinDavid T MajureKevin J ClerkinJason ChoeGabriel SayerNir Uriel

    Find these authors on Roon

    DL
    Dr. Dor Lotan
    Advanced Heart Failure · CUIMC

    Summary

    BACKGROUND: Cytomegalovirus (CMV) infection post-heart transplantation (HT) is associated with worse outcomes. Antiviral prophylaxis for at-risk patients is the standard of care. Valganciclovir, the most commonly used antiviral drug, is associated with significant adverse events, particularly leukopenia. Letermovir is a CMV-specific antiviral drug with a favorable side effect profile but its efficacy in HT recipients is unclear. This study aims to assess the safety and efficacy of letermovir for CMV prophylaxis in HT recipients.METHODS: This single-center retrospective analysis included HT recipients at our center from January 2020 to September 2023. Patients who were switched to letermovir for CMV prophylaxis for leukopenia/neutropenia on valganciclovir, and remained on letermovir for at least 60 days or developed CMV viremia on letermovir within 60 days of initiation were included. The primary endpoint was the incidence of CMV viremia/disease during letermovir therapy. Secondary endpoints included changes in white blood cell (WBC) count, tacrolimus dosing, and clinically significant acute rejection.RESULTS: A total of 52 patients received letermovir for an average of 8.2 months (range, 1-35 months). The average time from transplantation to letermovir initiation was 9.2 months (range, 0.9-77 months). Eight (15.4%) patients developed breakthrough CMV viremia on letermovir with a median viral load of 205 [IQR, 142.0-367.5] copies/mL; 4 of these patients were converted back to valganciclovir. Overall, 92.3% of patients completed therapy with letermovir. There were no episodes of suspected or biopsy-proven CMV disease. The majority of patients (78%) required dose reductions of tacrolimus following letermovir initiation, with no episodes of tacrolimus toxicity requiring hospitalization. WBC counts increased, on average, from 2.6 to 5.3 × 103 cells/μL (P < .001).CONCLUSION: Letermovir holds promise as an effective and safe alternative to valganciclovir for CMV prophylaxis in HT recipients.
    DLDr. Dor Lotan

    Dr. Dor Lotan

    Cardiology · Advanced Heart Failure & Transplantation
    Columbia University Irving Medical Center
    dor